867009-61-8

Basic information

• Product Name: 2-benzyl-2,8-diazaspiro[4.5]decane
• Synonyms: 2-benzyl-2,8-diazaspiro[4.5]decane;2,8-Diazaspiro[4.5]decane, 2-(phenylmethyl)-;2,8-Diazaspiro[4.5]decane, 2-(phenylMethyl)- HCl;2-(Phenylmethyl)-2,8-diazaspiro[4.5]decane;2-Benzyl-2,8-diazaspiro[4.5]decane hemioxalate
• CAS NO: 867009-61-8
• Molecular Formula: C15H22N2
• Molecular Weight: 230.353
• Mol File: 867009-61-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 340.8°C at 760 mmHg
• Flash Point: 134.1°C
• Appearance: /
• Density: 1.07
• Vapor Pressure: 8.37E-05mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-benzyl-2,8-diazaspiro[4.5]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-benzyl-2,8-diazaspiro[4.5]decane(867009-61-8)
• EPA Substance Registry System: 2-benzyl-2,8-diazaspiro[4.5]decane(867009-61-8)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 867009-61-8(Hazardous Substances Data)

Usage

Chemical Properties

Wihite powder

InChI:InChI=1/C15H22N2/c1-2-4-14(5-3-1)12-17-11-8-15(13-17)6-9-16-10-7-15/h1-5,16H,6-13H2

Upstream product

• 100-52-7 benzaldehyde 
• 236406-40-9 tert-butyl 2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 236406-39-6 2,8-diazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 716324-44-6 2-benzyl-2,8-diazaspiro[4.5]decan-1-one 
• 1221818-05-8 tert-butyl 2-benzyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 1228603-43-7 4-(2-oxoethyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 146603-99-8 1-(1,1-dimethylethyl) 4-ethyl 4-(2-propenyl)-1,4-piperidinedicarboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 15882-48-1 2-benzyl-2,8-diaza-spiro[4.5]decane-1,3-dione 

Relevant articles and documents

Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

A series of new 8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one(BTZ) derivatives containing a C-2 nitrogen spiro-heterocycle moiety based on the structures of BTZ candidates BTZ043 and PBTZ169 were designed and synthesized as new antitubercular agents. Many of them were found to have excellent in vitro activity (MIC 0.15 μM) against the drug susceptive Mycobacterium tuberculosis H37Rv strain and two clinically isolated multidrug-resistant strains. Compounds 11l and 11m display acceptable safety, greater aqueous solubility, and better pharmacokinetic profiles than PBTZ169, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

SUBSTITUTED DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS

This invention concerns substituted diaza-spiro-[4.5]-decane derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK2 antagonist ic activity, a combined NK1/NK3 antagonist ic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.